Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06914102 · ClinicalTrials.gov registry record

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

A clinical trial of Diabetes Mellitus, Type 2 and HFpEF - Heart Failure With Preserved Ejection Fraction, sponsored by Brigham and Women's Hospital.

Completed
Registry status
58,387
Enrollment target
1
Study location

NCT06914102 is a study of Diabetes Mellitus, Type 2 and HFpEF - Heart Failure With Preserved Ejection Fraction that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 58,387 participants, above the 4,318-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (1252% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06914102, a study of Diabetes Mellitus, Type 2 and HFpEF - Heart Failure With Preserved Ejection Fraction, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
58,387 participants
Enrollment target
1
Study location

Study Summary

Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Interventions

  • DRUG Placebo
  • DRUG Semaglutide

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 58,387 participants
Start Date 2025-01-14
Est. Completion 2025-06-01

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT06914102

The ClinicalTrials.gov registry entry for NCT06914102 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 58,387 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 4,318-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (1252% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06914102 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06914102 about?

NCT06914102 is a clinical study titled "Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...

What is the current status of trial NCT06914102?

This trial is currently completed. The enrollment target is 58,387 participants. The study started on 2025-01-14. Estimated completion is 2025-06-01.

What conditions does trial NCT06914102 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction.

What interventions are being tested in trial NCT06914102?

The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).

Who is sponsoring clinical trial NCT06914102?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06914102 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.